Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072747 | 0.94 | MAOB (0.31) | MAOBCYP3A4HTR2A | |
| SCHEMBL7073088 | 0.87 | MAOB (0.35) | MAOBCYP3A4HTR2AALDH1A1 | |
| SCHEMBL7070708 | 0.85 | MAOB (0.33) | MAOB | |
| SCHEMBL7075697 | 0.85 | MAOB (0.40) | MAOBCYP3A4TRPA1ALDH1A1LMNA | |
| SCHEMBL7072813 | 0.83 | MAOB (0.38) | MAOBCYP3A4TRPA1ALDH1A1LMNA | |
| SCHEMBL7075341 | 0.82 | MAOB (0.40) | MAOBCYP3A4HTR2ATRPA1ALDH1A1 | |
| SCHEMBL7070393 | 0.82 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7075796 | 0.82 | MAOB (0.37) | MAOBTRPA1ALDH1A1LMNAALOX5 | |
| SCHEMBL7069086 | 0.81 | TDP1 (0.37) | MAOBALDH1A1LMNA | |
| SCHEMBL7073901 | 0.81 | MAOB (0.36) | MAOBCYP3A4HTR2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109730-A1 | Transition metal compound, addition polymerization catalyst component, addition polymerization catalyst and process for production of olefin polymer | NABIKA MASAAKI (JP) | 2003-06-12 | — | — | US | disclosed |
| US-6528671-B1 | Such as cyclopentadienyl-trimethylphosphineimine-1,4-di-phenyl butandiene titanium complex; copolymerization of ethylene with other alpha-olefins | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109730-A1 | Transition metal compound, addition polymerization catalyst component, addition polymerization catalyst and process for production of olefin polymer | ARL1, AP2M1, AP1M1 | MAOB 1280/4885CYP3A4 1024/4885HTR2A 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.